TY - JOUR
T1 - Transplantation of multiciliated airway cells derived from human iPS cells using an artificial tracheal patch into rat trachea
AU - Okuyama, Hideaki
AU - Ohnishi, Hiroe
AU - Nakamura, Ryosuke
AU - Yamashita, Masaru
AU - Kishimoto, Yo
AU - Tateya, Ichiro
AU - Suehiro, Atsushi
AU - Gotoh, Shimpei
AU - Takezawa, Toshiaki
AU - Nakamura, Tatsuo
AU - Omori, Koichi
N1 - Publisher Copyright:
© 2019 John Wiley & Sons, Ltd.
PY - 2019/6
Y1 - 2019/6
N2 - Tracheal resection is often performed for malignant tumours, congenital anomalies, inflammatory lesions, and traumatic injuries. There is no consensus on the best approach for the restoration of tracheal functionality in patients with tracheal defects. Artificial grafts made of polypropylene and collagen sponge have been clinically used by our group. However, 2 months are required to achieve adequate epithelialization of the grafts in humans. This study aimed to investigate the feasibility of transplantation therapy using an artificial trachea with human-induced pluripotent stem cell (hiPSC)-derived multiciliated airway cells (hiPSC-MCACs). Collagen vitrigel membrane, a biocompatible and absorbable material, was used as a scaffold to cover the artificial trachea with hiPSC-MCACs. Analyses of hiPSC-MCACs on collagen vitrigel membrane were performed by immunocytochemistry and electron microscopy and by assessing ciliary beat frequency. Along with the artificial trachea, hiPSC-MCACs were transplanted into surgically created tracheal defects of immunodeficient rats. The survival of transplanted cells was histologically evaluated at 1 and 2 weeks after the transplantation. The hiPSC-MCACs exhibited motile cilia on collagen vitrigel membrane. The surviving hiPSC-MCACs were observed in the endotracheal epithelium of the tracheal defect at 1 and 2 weeks after transplantation. These results suggest that hiPSC-MCAC is a useful candidate for tracheal reconstruction.
AB - Tracheal resection is often performed for malignant tumours, congenital anomalies, inflammatory lesions, and traumatic injuries. There is no consensus on the best approach for the restoration of tracheal functionality in patients with tracheal defects. Artificial grafts made of polypropylene and collagen sponge have been clinically used by our group. However, 2 months are required to achieve adequate epithelialization of the grafts in humans. This study aimed to investigate the feasibility of transplantation therapy using an artificial trachea with human-induced pluripotent stem cell (hiPSC)-derived multiciliated airway cells (hiPSC-MCACs). Collagen vitrigel membrane, a biocompatible and absorbable material, was used as a scaffold to cover the artificial trachea with hiPSC-MCACs. Analyses of hiPSC-MCACs on collagen vitrigel membrane were performed by immunocytochemistry and electron microscopy and by assessing ciliary beat frequency. Along with the artificial trachea, hiPSC-MCACs were transplanted into surgically created tracheal defects of immunodeficient rats. The survival of transplanted cells was histologically evaluated at 1 and 2 weeks after the transplantation. The hiPSC-MCACs exhibited motile cilia on collagen vitrigel membrane. The surviving hiPSC-MCACs were observed in the endotracheal epithelium of the tracheal defect at 1 and 2 weeks after transplantation. These results suggest that hiPSC-MCAC is a useful candidate for tracheal reconstruction.
KW - artificial trachea
KW - collagen vitrigel membrane
KW - human-induced pluripotent stem cell
KW - multiciliated airway cell
KW - tracheal epithelialization
KW - tracheal reconstruction
UR - http://www.scopus.com/inward/record.url?scp=85065033269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065033269&partnerID=8YFLogxK
U2 - 10.1002/term.2849
DO - 10.1002/term.2849
M3 - Article
C2 - 30809958
AN - SCOPUS:85065033269
SN - 1932-6254
VL - 13
SP - 1019
EP - 1030
JO - Journal of Tissue Engineering and Regenerative Medicine
JF - Journal of Tissue Engineering and Regenerative Medicine
IS - 6
ER -